Median Technologies announced the launch of a €40 million capital increase, with the potential to increase to €50 million, to support the commercial deployment of its AI-powered eyonis LCS lung cancer screening platform in the United States and Europe while advancing additional cancer indications across its eyonis portfolio.
The financing includes a share capital increase without shareholders’ preferential subscription rights through a public offering of ordinary shares. The company also established a reserved offering for guarantors of up to €10 million if the public offering is fully subscribed. Median Technologies has already secured €30 million in subscription and backstop commitments, representing 75% of the public offering.
The subscription price was set at €5 per ordinary share. Median Technologies said the proceeds will primarily fund the commercial rollout of eyonis LCS in the U.S. and Europe, support development of new AI-based Software as Medical Devices for additional cancer indications, and provide working capital through the first half of 2028.
Median Technologies said its eyonis LCS platform received FDA 510(k) clearance in February 2026, enabling commercialization of the AI-based detection and diagnosis software for lung cancer screening in the United States. The company said the platform achieved 93.3% sensitivity, 92.4% specificity, and a 99.9% negative predictive value in clinical performance metrics.
The company estimates the annual total addressable market for lung cancer screening in the U.S. exceeds $9 billion, driven by approximately 14.5 million eligible individuals and reimbursement frameworks that can provide around $650 per procedure for AI-based analyses.
Median Technologies highlighted several commercialization milestones, including a non-exclusive partnership agreement with Tempus AI to integrate eyonis LCS into the Tempus Pixel platform, the appointment of Oran Muduroglu as President of Median eyonis Inc., and the expansion of a multi-channel go-to-market strategy targeting independent diagnostic testing facilities and the U.S. Veterans Affairs healthcare system.
The company also expects a CE marking decision for eyonis LCS in Europe within the coming weeks, which would support deployment across several European countries, including Germany, Poland, Italy, and France.
Beyond lung cancer screening, Median Technologies said it plans to expand the eyonis platform into additional indications including incidental pulmonary nodules and hepatocellular carcinoma, with long-term ambitions to address pancreatic, colorectal, prostate, and liver cancers through AI-powered imaging diagnostics.
The offering is being led by TD Cowen and Stifel as joint global coordinators and joint placement agents. The public offering subscription period is scheduled to close on June 3, 2026, with issuance and trading of the new shares expected to begin on June 9, 2026.
KEY QUOTES:
“The defining truth in oncology is simple: outcomes are determined by the stage at which cancer is diagnosed. When cancer is diagnosed early, it is often curable. When diagnosed late, it becomes complex, costly, and frequently fatal. Despite major advances in treatment, most healthcare systems remain structurally focused on late-stage disease. A structural shift is now possible: advances in AI applied to medical imaging make large-scale early cancer diagnosis operational.
Median Technologies operates at the convergence of three powerful forces: AI, medical imaging, and early cancer diagnosis. Our proprietary eyonis platform is designed to develop multiple AI-based SaMD for the early detection and diagnosis of cancers within existing clinical workflows and to act as a force multiplier for healthcare systems.
Our first indication, eyonis LCS for lung cancer screening, achieved FDA 510(k) clearance in February 2026. eyonis LCS is positioned as a clinically validated and deployable SaMD combining early identification with clinically actionable diagnostic decision support. This places us at the forefront of a shift from treating cancer reactively to driving early-stage curative diagnosis.
This financing is intended to fund the U.S. commercial rollout of eyonis LCS in the lung cancer screening indication, and allows us to launch our device in Europe after CE mark achievement. It will also enable the Company to continue and accelerate the development of additional AI-based Software as Medical Devices within the eyonis portfolio, targeting new cancer indications. It will provide the Company with a cash runway until the first half-year 2028, when we expect to have demonstrated meaningful commercial traction in lung cancer. We welcome Lion Point Capital’s and the Guarantors’ continued and reinforced commitment, which provides all our existing shareholders the opportunity to participate in this important next phase, while ensuring the Company has the resources required to deliver on its strategic priorities.”
Fredrik Brag, CEO and Founder, Median Technologies
